BRKB

482.48

+0.25%↑

BRKA.US

723,302.5

+0.24%↑

JPM

295.21

+1.24%↑

V

304.35

-0.6%↓

MA

499.75

-0.69%↓

BRKB

482.48

+0.25%↑

BRKA.US

723,302.5

+0.24%↑

JPM

295.21

+1.24%↑

V

304.35

-0.6%↓

MA

499.75

-0.69%↓

BRKB

482.48

+0.25%↑

BRKA.US

723,302.5

+0.24%↑

JPM

295.21

+1.24%↑

V

304.35

-0.6%↓

MA

499.75

-0.69%↓

BRKB

482.48

+0.25%↑

BRKA.US

723,302.5

+0.24%↑

JPM

295.21

+1.24%↑

V

304.35

-0.6%↓

MA

499.75

-0.69%↓

BRKB

482.48

+0.25%↑

BRKA.US

723,302.5

+0.24%↑

JPM

295.21

+1.24%↑

V

304.35

-0.6%↓

MA

499.75

-0.69%↓

Search

Victory Capital Holdings Inc

Avatud

SektorRahandus

67.9 -1.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

67.25

Max

68.81

Põhinäitajad

By Trading Economics

Sissetulek

16M

113M

Müük

13M

374M

P/E

Sektori keskmine

16.51

54.048

Aktsiakasum

1.78

Dividenditootlus

2.91

Kasumimarginaal

30.154

Töötajad

699

EBITDA

-219K

168M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+8.89% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

2.91%

4.84%

Järgmine tulemuste avaldamine

7. mai 2026

Järgmine dividendimakse kuupäev

25. märts 2026

Järgmine aktsia dividendi kuupäev (ex-date)

9. juuni 2026

Turustatistika

By TradingEconomics

Turukapital

-382M

4.4B

Eelmine avamishind

69.18

Eelmine sulgemishind

67.9

Uudiste sentiment

By Acuity

50%

50%

160 / 441 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Victory Capital Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. märts 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23. märts 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23. märts 2026, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23. märts 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23. märts 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23. märts 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23. märts 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Global Equities Roundup: Market Talk

23. märts 2026, 22:42 UTC

Market Talk
Uudisväärsed sündmused

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23. märts 2026, 22:40 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23. märts 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23. märts 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23. märts 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23. märts 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23. märts 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23. märts 2026, 22:18 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23. märts 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23. märts 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23. märts 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. märts 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23. märts 2026, 21:32 UTC

Tulu

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23. märts 2026, 21:10 UTC

Uudisväärsed sündmused

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23. märts 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23. märts 2026, 20:50 UTC

Market Talk
Tulu
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Victory Capital Holdings Inc Prognoos

Hinnasiht

By TipRanks

8.89% tõus

12 kuu keskmine prognoos

Keskmine 74.25 USD  8.89%

Kõrge 84 USD

Madal 69 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Victory Capital Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

2

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

59.07 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

160 / 441 Pingereas Rahandus

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Victory Capital Holdings Inc

Victory Capital Holdings, Inc., together with its subsidiaries, operates as an asset management company in the United States and internationally. It offers investment advisory, fund administration, fund compliance, fund transfer agent, fund distribution, and other management services. The company provides specialized investment strategies to institutions, intermediaries, retirement platforms, and individual investors. Its investment products include actively and passively managed mutual funds; rules-based and active exchange traded funds; institutional separate accounts; variable insurance products; alternative investments; and private closed-end funds; and a 529 Education Savings Plan. The company also offers strategies through third-party investment products, including mutual funds, third-party ETF model strategies, retail separately managed accounts, unified managed accounts through wrap account programs, Collective Investment Trusts, and undertakings for the collective investment in transferable securities. Victory Capital Holdings, Inc. was incorporated in 2013 and is based in San Antonio, Texas.
help-icon Live chat